重型颅脑创伤后脑组织氧分压监测的使用情况及其与死亡率的关系
该回顾性队列研究利用美国外科医师学会国家创伤数据库2008—2016年数据,纳入年龄>18岁、入院格拉斯哥昏迷评分≤8分、存活超过24小时且需颅内压监测的重型颅脑创伤患者共35,501例。其中1,346例(3.8%)同时放置脑组织氧分压监测,使用率随日历年及医院差异显著。倾向加权回归显示,脑组织氧分压监测组院内死亡率31.1%,仅颅内压监测组33.5%(校正风险比0.84,95%置信区间0.76–0.93);ARDS发生率9.2% vs 9.8%(校正风险比0.89,95%置信区间0.73–1.09)。作者认为该结果可为临床医生在等待进一步随机对照试验完成期间提供参考。
要点
- 研究纳入35,501例需颅内压监测的重型颅脑创伤患者,仅1,346例(3.8%)加用脑组织氧分压监测,使用率随日历年及医院差异显著。
- 加用脑组织氧分压监测组院内死亡率31.1%,仅颅内压监测组33.5%,校正风险比0.84(95%置信区间0.76–0.93)。
- 两组ARDS发生率相近:脑组织氧分压监测组9.2% vs 仅颅内压监测组9.8%,校正风险比0.89(95%置信区间0.73–1.09)。
- 作者报告加用脑组织氧分压监测与住院时间延长相关。
- 作者认为该发现可为重型颅脑创伤患者的临床管理提供参考,同时等待进一步随机对照试验完成。
适用人群与场景
- 美国创伤中心参与美国外科医师学会国家创伤数据库的2008—2016年患者。
- 年龄>18岁、入院格拉斯哥昏迷评分≤8分、存活超过24小时且需颅内压监测的重型颅脑创伤患者。
诊断标准与关键阈值
- 重型颅脑创伤定义为入院格拉斯哥昏迷评分≤8分。
- 纳入标准还包括年龄>18岁、存活超过24小时且需颅内压监测。
研究设计与关键结果
- 研究类型为回顾性队列研究,数据来自美国外科医师学会国家创伤数据库2008—2016年,共35,501例放置颅内压监测的患者。
- 其中1,346例(3.8%)同时放置脑组织氧分压监测,使用率随日历年及医院差异显著。
- 主要终点院内死亡率(住院期间死亡或出院转临终关怀):脑组织氧分压监测组31.1% vs 仅颅内压监测组33.5%,校正风险比0.84(95%置信区间0.76–0.93)。
- 次要终点ARDS发生率:脑组织氧分压监测组9.2% vs 仅颅内压监测组9.8%,校正风险比0.89(95%置信区间0.73–1.09)。
- 次要终点住院时间:脑组织氧分压监测组住院时间更长。
- 采用倾向加权回归分析处理非随机分组所致选择偏倚及患者脱落。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在等待进一步随机对照试验完成期间,该发现可为照顾重型颅脑创伤患者的临床医生提供参考。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The aim of this study was to describe the utilization patterns of brain tissue oxygen (PbtO2) monitoring following severe traumatic brain injury (TBI) and determine associations with mortality, health care use, and pulmonary toxicity.
METHODS: We conducted a retrospective cohort study of patients from United States trauma centers participating in the American College of Surgeons National Trauma Databank between 2008 and 2016. We examined patients with severe TBI (defined by admission Glasgow Coma Scale score ≤ 8) over the age of 18 years who survived more than 24 h from admission and required intracranial pressure (ICP) monitoring. The primary exposure was PbtO2 monitor placement. The primary outcome was hospital mortality, defined as death during the hospitalization or discharge to hospice. Secondary outcomes were examined to determine the association of PbtO2 monitoring with health care use and pulmonary toxicity and included the following: (1) intensive care unit length of stay, (2) hospital length of stay, and (3) development of acute respiratory distress syndrome (ARDS). Regression analysis was used to assess differences in outcomes between patients exposed to PbtO2 monitor placement and those without exposure by using propensity weighting to address selection bias due to the nonrandom allocation of treatment groups and patient dropout.
RESULTS: A total of 35,501 patients underwent placement of an ICP monitor. There were 1,346 (3.8%) patients who also underwent PbtO2 monitor placement, with significant variation regarding calendar year and hospital. Patients who underwent placement of a PbtO2 monitor had a crude in-hospital mortality of 31.1%, compared with 33.5% in patients who only underwent placement of an ICP monitor (adjusted risk ratio 0.84, 95% confidence interval 0.76-0.93). The development of the ARDS was comparable between patients who underwent placement of a PbtO2 monitor and patients who only underwent placement of an ICP monitor (9.2% vs. 9.8%, adjusted risk ratio 0.89, 95% confidence interval 0.73-1.09).
CONCLUSIONS: PbtO2 monitor utilization varied widely throughout the study period by calendar year and hospital. PbtO2 monitoring in addition to ICP monitoring, compared with ICP monitoring alone, was associated with a decreased in-hospital mortality, a longer length of stay, and a similar risk of ARDS. These findings provide further guidance for clinicians caring for patients with severe TBI while awaiting completion of further randomized controlled trials.
参考来源
- Komisarow JM, Toro C, Curley J, et al. Utilization of Brain Tissue Oxygenation Monitoring and Association with Mortality Following Severe Traumatic Brain Injury. Neurocrit Care. 2021. PMID: 34845596. doi:10.1007/s12028-021-01394-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。